---
title: "Tilidin - Complete Profile"
substance: "Tilidin"
chemical_name: "Tilidine hydrochloride"
category: "Depressant"
legal_status: "Schedule II (Germany), Prescription Only"
description: "German synthetic opioid analgesic - tramadol's clinical cousin with naloxone abuse-deterrent formulation"
permalink: "/dyos-domain/substances/tilidin/"
---

<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/depressants/">Depressants</a> ‚Üí <span>Tilidin</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíä Tilidin</h1>
        <h2 class="chemical-name">Tilidine hydrochloride</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Tilidin" 
                data-category="Depressants" 
                data-chemical="Tilidine hydrochloride">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Forms</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Generic Names</h4>
              <span>Tilidine</span> ‚Ä¢ <span>Tilidin HCl</span> ‚Ä¢ <span>Trans-2-(dimethylamino)-1-phenyl-3-cyclohexene-1-carboxylic acid ethyl ester</span>
            </div>
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Valoron</span> ‚Ä¢ <span>Valtran</span> ‚Ä¢ <span>Tilicomp</span> ‚Ä¢ <span>Tilidolor</span> ‚Ä¢ <span>Tilidin-ratiopharm</span>
            </div>
            <div class="name-category">
              <h4>Combination Products</h4>
              <span>Tilidin + Naloxone</span> ‚Ä¢ <span>Valoron N</span> ‚Ä¢ <span>Tilicomp plus</span> ‚Ä¢ <span>Tili/Nalox</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Tilis</span> ‚Ä¢ <span>German Tramadol</span> ‚Ä¢ <span>Euro Pills</span> ‚Ä¢ <span>V-Pills</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status prescription">Prescription</span>
          <span class="duration medium">3-6 hours</span>
          <span class="medical">Medical</span>
          <span class="addiction-risk moderate">Moderate Risk</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/tilidin.jpg" alt="Tilidin tablets, capsules, and oral drops with German pharmaceutical packaging" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>‚öóÔ∏è C‚ÇÅ‚ÇáH‚ÇÇ‚ÇÉNO‚ÇÇ</p>
            <p>MW: 273.37 g/mol</p>
            <p>Synthetic opioid</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pharmaceutical-forms">
          <h4>Pharmaceutical Preparations</h4>
          <ul>
            <li><strong>Tablets:</strong> White to off-white, scored or unscored, various strengths</li>
            <li><strong>Capsules:</strong> Hard gelatin capsules, often two-toned colors</li>
            <li><strong>Oral drops:</strong> Clear to pale yellow liquid solution</li>
            <li><strong>Extended-release:</strong> Retard formulations for 12-hour dosing</li>
            <li><strong>Suppositories:</strong> Rectal administration for specific indications</li>
          </ul>
        </div>
        
        <div class="standard-preparations">
          <h4>Standard Dosage Forms</h4>
          <div class="preparation-type">
            <h5>üíä Tilidin Monotherapy</h5>
            <ul>
              <li><strong>Immediate-release tablets:</strong> 50mg, 100mg</li>
              <li><strong>Capsules:</strong> 50mg, 100mg</li>
              <li><strong>Oral drops:</strong> 2.5mg/ml, 40 drops = 100mg</li>
              <li><strong>Extended-release:</strong> 100mg, 150mg, 200mg</li>
            </ul>
          </div>
          
          <div class="preparation-type">
            <h5>üö´ Tilidin/Naloxone Combinations</h5>
            <ul>
              <li><strong>Standard ratio:</strong> 8:1 (tilidin:naloxone)</li>
              <li><strong>Tablets:</strong> 50mg/6.25mg, 100mg/8mg</li>
              <li><strong>Drops:</strong> 2.5mg/0.25mg per ml</li>
              <li><strong>Retard formulations:</strong> 100mg/8mg, 150mg/12mg, 200mg/16mg</li>
            </ul>
          </div>
          
          <div class="preparation-type">
            <h5>üè• Hospital/IV Preparations</h5>
            <ul>
              <li><strong>Injectable solution:</strong> 50mg/ml in 2ml ampoules</li>
              <li><strong>IV administration:</strong> Hospital use only</li>
              <li><strong>Intramuscular:</strong> Alternative parenteral route</li>
            </ul>
          </div>
        </div>
        
        <div class="naloxone-identification">
          <h4>üö´ Naloxone Co-formulation Identification</h4>
          <ul>
            <li><strong>Purpose:</strong> Abuse-deterrent to prevent injection/snorting</li>
            <li><strong>Oral activity:</strong> Naloxone inactive orally - doesn't block effects</li>
            <li><strong>Injection deterrent:</strong> Naloxone active parenterally - blocks high</li>
            <li><strong>Packaging identification:</strong> "N" suffix, "plus" designation</li>
            <li><strong>German standard:</strong> Most tilidin now includes naloxone</li>
          </ul>
        </div>
        
        <div class="street-identification">
          <h4>üíä Street/Diverted Forms</h4>
          <ul>
            <li><strong>German packaging:</strong> Distinctive European pharmaceutical design</li>
            <li><strong>Blister packs:</strong> Individual foil-backed compartments</li>
            <li><strong>Prescription labels:</strong> German text, patient information</li>
            <li><strong>Abuse indicators:</strong> Crushed tablets, extracted solutions</li>
            <li><strong>Counterfeit risk:</strong> Lower than other opioids due to regional nature</li>
          </ul>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      
      <div class="dosage-warning medical">
        <h4>üè• MEDICAL SUPERVISION REQUIRED</h4>
        <p><strong>Prescription medication:</strong> Tilidin is a prescription opioid analgesic that requires medical supervision. Self-medication with diverted pharmaceutical supplies carries significant addiction and overdose risks.</p>
      </div>

      <div class="dosage-by-indication">
        <h4>Medical Dosage Guidelines</h4>
        
        <div class="dosage-indication">
          <h5>üè• Moderate to Severe Pain</h5>
          <div class="dose-range medical">
            <span class="range-label">Initial dose</span>
            <span class="dose-amount">50-100mg</span>
          </div>
          <div class="dose-range medical">
            <span class="range-label">Maintenance</span>
            <span class="dose-amount">50-100mg q4-6h</span>
          </div>
          <div class="dose-range medical">
            <span class="range-label">Maximum daily</span>
            <span class="dose-amount">400-600mg</span>
          </div>
        </div>

        <div class="dosage-indication">
          <h5>üë¥ Elderly Patients</h5>
          <div class="dose-range elderly">
            <span class="range-label">Initial dose</span>
            <span class="dose-amount">25-50mg</span>
          </div>
          <div class="dose-range elderly">
            <span class="range-label">Maintenance</span>
            <span class="dose-amount">50mg q6-8h</span>
          </div>
          <div class="dose-range elderly">
            <span class="range-label">Maximum daily</span>
            <span class="dose-amount">300mg</span>
          </div>
        </div>

        <div class="dosage-indication">
          <h5>‚ö†Ô∏è Recreational/Diverted Use</h5>
          <div class="dose-range threshold">
            <span class="range-label">Threshold</span>
            <span class="dose-amount">25-50mg</span>
          </div>
          <div class="dose-range light">
            <span class="range-label">Light</span>
            <span class="dose-amount">50-75mg</span>
          </div>
          <div class="dose-range common">
            <span class="range-label">Common</span>
            <span class="dose-amount">75-150mg</span>
          </div>
          <div class="dose-range dangerous">
            <span class="range-label">High risk</span>
            <span class="dose-amount">200mg+</span>
          </div>
        </div>
      </div>
      
      <div class="naloxone-impact">
        <h4>üö´ Naloxone Co-formulation Impact</h4>
        <ul>
          <li><strong>Oral use:</strong> Naloxone has no effect - full tilidin activity</li>
          <li><strong>Intranasal:</strong> Partial naloxone absorption reduces effects</li>
          <li><strong>Injection:</strong> Naloxone fully active - blocks euphoria, precipitates withdrawal</li>
          <li><strong>Sublingual:</strong> Mixed absorption - unpredictable effects</li>
          <li><strong>Abuse deterrent:</strong> Significantly reduces injection/snorting abuse</li>
        </ul>
      </div>

      <div class="dosage-considerations">
        <h4>Clinical Dosage Considerations</h4>
        <ul>
          <li><strong>Hepatic impairment:</strong> Reduce dose 50% - impaired metabolism</li>
          <li><strong>Renal impairment:</strong> Dose adjustment needed for severe dysfunction</li>
          <li><strong>Opioid-naive patients:</strong> Start with lowest effective dose</li>
          <li><strong>Conversion ratios:</strong> ~0.1-0.2x morphine potency</li>
          <li><strong>Tolerance development:</strong> Occurs within 1-2 weeks of regular use</li>
          <li><strong>Withdrawal prevention:</strong> Taper gradually over 7-14 days</li>
        </ul>
      </div>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Oral Administration)</h4>
        <div class="timeline-item">
          <span class="time">T+0:15-0:45</span>
          <span class="effect">Onset - initial analgesia, mood lift</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:45-2:00</span>
          <span class="effect">Peak - maximum analgesia, euphoria (if present)</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-4:00</span>
          <span class="effect">Plateau - sustained pain relief, mild sedation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Comedown - gradual return to baseline, possible rebound pain</span>
        </div>
      </div>

      <div class="effects-timeline">
        <h4>Timeline (Extended-Release)</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:30</span>
          <span class="effect">Onset - gradual analgesia development</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:30-8:00</span>
          <span class="effect">Sustained - consistent pain relief, stable effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-12:00</span>
          <span class="effect">Extended - continued analgesia, minimal euphoria</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+12:00+</span>
          <span class="effect">Offset - gradual return, next dose timing</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category therapeutic">
          <h4>‚úÖ Therapeutic Effects</h4>
          <ul>
            <li>Effective analgesia for moderate-severe pain</li>
            <li>Improved functional capacity</li>
            <li>Reduced pain-related sleep disturbance</li>
            <li>Enhanced quality of life in chronic pain</li>
            <li>Less respiratory depression than morphine</li>
            <li>Antitussive (cough suppressing) effects</li>
            <li>Anxiolytic properties in pain patients</li>
          </ul>
        </div>
        
        <div class="effect-category recreational">
          <h4>üåü Recreational Effects (Abuse Potential)</h4>
          <ul>
            <li>Mild to moderate euphoria</li>
            <li>Emotional numbing/detachment</li>
            <li>Relaxation and stress relief</li>
            <li>Warm, comfortable sensations</li>
            <li>Reduced anxiety and worry</li>
            <li>Slight mood elevation</li>
            <li>Social disinhibition (mild)</li>
          </ul>
        </div>

        <div class="effect-category negative">
          <h4>‚ùå Adverse Effects</h4>
          <ul>
            <li>Nausea and vomiting (especially initial doses)</li>
            <li>Constipation (common with chronic use)</li>
            <li>Drowsiness and sedation</li>
            <li>Dizziness and lightheadedness</li>
            <li>Dry mouth</li>
            <li>Sweating disturbances</li>
            <li>Cognitive impairment and confusion</li>
            <li>Urinary retention</li>
          </ul>
        </div>

        <div class="effect-category withdrawal">
          <h4>üîÑ Withdrawal Effects</h4>
          <ul>
            <li><strong>Early (6-12 hours):</strong> Anxiety, restlessness, drug cravings</li>
            <li><strong>Peak (24-72 hours):</strong> Muscle aches, nausea, insomnia, irritability</li>
            <li><strong>Physical symptoms:</strong> Runny nose, tearing, goosebumps, diarrhea</li>
            <li><strong>Psychological:</strong> Depression, anxiety, anhedonia</li>
            <li><strong>Duration:</strong> Acute phase 5-7 days, PAWS weeks to months</li>
            <li><strong>Severity:</strong> Moderate compared to stronger opioids</li>
          </ul>
        </div>
      </div>

      <div class="tramadol-comparison">
        <h4>üîÑ Comparison with Tramadol</h4>
        <div class="comparison-aspects">
          <div class="comparison-aspect">
            <h5>Similarities</h5>
            <ul>
              <li>Moderate potency synthetic opioids</li>
              <li>Dual mechanism of action (opioid + monoamine)</li>
              <li>Lower abuse potential than traditional opioids</li>
              <li>Effective for moderate pain</li>
              <li>Both have SNRI-like properties</li>
            </ul>
          </div>
          
          <div class="comparison-aspect">
            <h5>Differences</h5>
            <ul>
              <li><strong>Regional availability:</strong> Tilidin primarily European</li>
              <li><strong>Abuse deterrent:</strong> Tilidin often combined with naloxone</li>
              <li><strong>Metabolic pathway:</strong> Different CYP enzyme dependencies</li>
              <li><strong>Seizure risk:</strong> Tilidin has lower seizure threshold lowering</li>
              <li><strong>Euphoria:</strong> Tilidin slightly more euphoric potential</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Tilidin is a synthetic opioid analgesic with dual mechanism of action. It acts as a mu-opioid receptor agonist (after conversion to active metabolite nortilidine) while also inhibiting the reuptake of norepinephrine and serotonin. This dual action provides both traditional opioid analgesia and additional pain relief through monoaminergic pathways, similar to tramadol but with distinct pharmacological properties.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œº-opioid receptors (MOR)</strong></span>
            <span class="affinity">Moderate affinity (nortilidine metabolite)</span>
            <span class="function">Primary analgesia, mild euphoria, respiratory depression</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Norepinephrine transporter (NET)</strong></span>
            <span class="affinity">Moderate inhibition</span>
            <span class="function">Enhanced descending pain inhibition, mood effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Serotonin transporter (SERT)</strong></span>
            <span class="affinity">Weak inhibition</span>
            <span class="function">Additional pain modulation, mood effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ¥-opioid receptors (DOR)</strong></span>
            <span class="affinity">Very low affinity</span>
            <span class="function">Minimal contribution to effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ∫-opioid receptors (KOR)</strong></span>
            <span class="affinity">Negligible affinity</span>
            <span class="function">No significant interaction</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Prodrug activation:</strong> Tilidin is a prodrug - converted to active nortilidine by N-demethylation</p>
          <p><strong>Primary enzyme:</strong> CYP3A4 and CYP2C19 mediated metabolism</p>
          <p><strong>Active metabolite:</strong> Nortilidine provides primary opioid activity</p>
          <p><strong>Half-life:</strong> Tilidin 2.5-3 hours, nortilidine 3-5 hours</p>
          <p><strong>Bioavailability:</strong> ~99% oral bioavailability (high)</p>
          <p><strong>Peak plasma:</strong> 25-50 minutes (immediate release)</p>
          <p><strong>Duration:</strong> 4-6 hours (immediate), 8-12 hours (extended-release)</p>
        </div>

        <h4>Naloxone Co-formulation Pharmacology</h4>
        <div class="naloxone-details">
          <p><strong>Oral naloxone:</strong> Poor oral bioavailability (~2%) - minimal systemic effects</p>
          <p><strong>First-pass metabolism:</strong> Extensive hepatic metabolism eliminates naloxone orally</p>
          <p><strong>Parenteral naloxone:</strong> High bioavailability (>80%) - blocks opioid effects</p>
          <p><strong>Competitive antagonism:</strong> Naloxone competes with nortilidine at mu-opioid receptors</p>
          <p><strong>Duration mismatch:</strong> Naloxone shorter duration than tilidin - repeated dosing needed</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Ceiling effect:</strong> Limited respiratory depression compared to traditional opioids</li>
          <li><strong>Dual analgesia:</strong> Opioid + monoaminergic pain relief mechanisms</li>
          <li><strong>Lower abuse potential:</strong> Less euphoric than morphine or oxycodone</li>
          <li><strong>Seizure risk:</strong> Lower than tramadol but still present at high doses</li>
          <li><strong>CYP interactions:</strong> Subject to drug interactions via CYP3A4 inhibition/induction</li>
          <li><strong>German specificity:</strong> Primarily developed and used in German-speaking countries</li>
        </ul>

        <h4>Tolerance & Dependence Mechanisms</h4>
        <div class="tolerance-mechanisms">
          <h5>üß† Tolerance Development</h5>
          <ul>
            <li><strong>Receptor downregulation:</strong> Chronic mu-opioid receptor stimulation</li>
            <li><strong>Compensatory mechanisms:</strong> Upregulation of cAMP pathways</li>
            <li><strong>Timeline:</strong> Noticeable tolerance within 1-2 weeks of regular use</li>
            <li><strong>Cross-tolerance:</strong> Complete with other mu-opioid agonists</li>
            <li><strong>Monoamine tolerance:</strong> Additional tolerance to SNRI-like effects</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Safety Warnings</h4>
          <ul>
            <li><strong>Respiratory depression:</strong> Can be fatal, especially with alcohol/benzos</li>
            <li><strong>Seizure risk:</strong> Increased at high doses or with predisposing factors</li>
            <li><strong>Physical dependence:</strong> Develops within 1-2 weeks of regular use</li>
            <li><strong>Serotonin syndrome:</strong> Risk when combined with SSRI/SNRI medications</li>
            <li><strong>Driving impairment:</strong> Significantly affects coordination and reaction time</li>
          </ul>
        </div>
        
        <div class="safety-item medical">
          <h4>üè• Medical Contraindications</h4>
          <ul>
            <li><strong>Respiratory conditions:</strong> COPD, sleep apnea, severe asthma</li>
            <li><strong>Head injury:</strong> Increased intracranial pressure risk</li>
            <li><strong>Liver disease:</strong> Impaired metabolism, increased toxicity</li>
            <li><strong>Kidney disease:</strong> Reduced elimination, dose adjustment needed</li>
            <li><strong>Seizure disorders:</strong> Lowers seizure threshold</li>
            <li><strong>Pregnancy:</strong> Neonatal withdrawal syndrome</li>
          </ul>
        </div>
        
        <div class="safety-item harm-reduction">
          <h4>üõ°Ô∏è Harm Reduction Strategies</h4>
          <ul>
            <li><strong>Medical supervision:</strong> Use only under physician guidance</li>
            <li><strong>Dose adherence:</strong> Never exceed prescribed amounts</li>
            <li><strong>Avoid alcohol:</strong> Dangerous respiratory depression synergy</li>
            <li><strong>Monitor tolerance:</strong> Report decreased effectiveness to doctor</li>
            <li><strong>Gradual tapering:</strong> Never stop abruptly after regular use</li>
            <li><strong>Safe storage:</strong> Secure from children and potential abuse</li>
          </ul>
        </div>
      </div>

      <div class="naloxone-safety">
        <h4>üö´ Naloxone Co-formulation Safety</h4>
        <div class="naloxone-benefits">
          <h5>Abuse Deterrent Benefits</h5>
          <ul>
            <li><strong>Injection deterrent:</strong> Naloxone blocks euphoria when injected</li>
            <li><strong>Nasal deterrent:</strong> Partial naloxone absorption reduces high</li>
            <li><strong>Overdose protection:</strong> Some naloxone absorption may reduce respiratory depression</li>
            <li><strong>Addiction prevention:</strong> Reduced reinforcement from abuse routes</li>
          </ul>
        </div>
        
        <div class="naloxone-limitations">
          <h5>Limitations & Considerations</h5>
          <ul>
            <li><strong>Oral route unaffected:</strong> Full tilidin effects when swallowed</li>
            <li><strong>Extraction possible:</strong> Sophisticated users may separate compounds</li>
            <li><strong>Withdrawal precipitation:</strong> Naloxone can trigger withdrawal in dependent users</li>
            <li><strong>Variable formulations:</strong> Different tilidin:naloxone ratios exist</li>
          </ul>
        </div>
      </div>

      <div class="overdose-recognition">
        <h4>üöë Overdose Recognition & Response</h4>
        <div class="overdose-signs">
          <h5>Signs of Tilidin Overdose</h5>
          <ul>
            <li><strong>Respiratory:</strong> Slow, shallow breathing or respiratory arrest</li>
            <li><strong>Consciousness:</strong> Extreme drowsiness, unresponsiveness, coma</li>
            <li><strong>Circulatory:</strong> Weak pulse, low blood pressure, blue lips/fingernails</li>
            <li><strong>Neurological:</strong> Pinpoint pupils, muscle limpness, cold skin</li>
            <li><strong>Unique signs:</strong> Possible seizures at very high doses</li>
          </ul>
        </div>
        
        <div class="overdose-response">
          <h5>Emergency Response Protocol</h5>
          <ul>
            <li><strong>Call emergency services:</strong> Immediate medical attention required</li>
            <li><strong>Naloxone administration:</strong> Give naloxone if available - may need multiple doses</li>
            <li><strong>Airway management:</strong> Position for breathing, provide rescue breaths if needed</li>
            <li><strong>Monitor closely:</strong> Naloxone duration shorter than tilidin</li>
            <li><strong>Hospital transport:</strong> Extended monitoring needed due to long half-life</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous Combinations</h4>
          <ul>
            <li><strong>CNS depressants:</strong> Alcohol, benzodiazepines, barbiturates - respiratory depression</li>
            <li><strong>MAOIs:</strong> Risk of serotonin syndrome, hypertensive crisis</li>
            <li><strong>SSRIs/SNRIs:</strong> Serotonin syndrome, especially with high doses</li>
            <li><strong>Other opioids:</strong> Additive respiratory depression, overdose risk</li>
            <li><strong>Muscle relaxants:</strong> Enhanced sedation, respiratory compromise</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High-Risk Combinations</h4>
          <ul>
            <li><strong>Antihistamines:</strong> Increased sedation, cognitive impairment</li>
            <li><strong>Sleep medications:</strong> Dangerous CNS depression</li>
            <li><strong>Anticonvulsants:</strong> Complex interactions, monitoring needed</li>
            <li><strong>Beta-blockers:</strong> Enhanced cardiovascular depression</li>
            <li><strong>Tricyclic antidepressants:</strong> Increased anticholinergic effects</li>
          </ul>
        </div>
        
        <div class="interaction medical">
          <h4>üíä Medical Drug Interactions</h4>
          <ul>
            <li><strong>CYP3A4 inhibitors:</strong> Ketoconazole, grapefruit juice - increased tilidin levels</li>
            <li><strong>CYP3A4 inducers:</strong> Rifampin, St. John's wort - reduced effectiveness</li>
            <li><strong>Warfarin:</strong> Potential bleeding risk, monitor INR</li>
            <li><strong>Digoxin:</strong> Possible enhanced cardiac effects</li>
            <li><strong>Diuretics:</strong> Increased risk of urinary retention</li>
          </ul>
        </div>
        
        <div class="interaction pharmacokinetic">
          <h4>‚öóÔ∏è Pharmacokinetic Interactions</h4>
          <ul>
            <li><strong>Metabolism inhibition:</strong> Drugs affecting CYP3A4 alter tilidin conversion</li>
            <li><strong>Protein binding:</strong> Highly protein-bound drugs may displace tilidin</li>
            <li><strong>Renal clearance:</strong> Drugs affecting kidney function alter elimination</li>
            <li><strong>Gastric pH:</strong> Antacids may affect absorption rate</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá©üá™ Germany</h4>
            <p><strong>Bet√§ubungsmittel-Verschreibungsverordnung (BtMVV)</strong> - Schedule II controlled substance. Prescription required, subject to narcotics regulations.</p>
            <p><strong>Medical use:</strong> Widely prescribed for moderate to severe chronic pain</p>
            <p><strong>Abuse deterrent mandate:</strong> Most formulations now include naloxone</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üáπ Austria</h4>
            <p><strong>Suchtmittelgesetz</strong> - Controlled substance, prescription only medicine.</p>
            <p><strong>Medical availability:</strong> Available for legitimate medical use</p>
          </div>
          <div class="jurisdiction">
            <h4>üá®üá≠ Switzerland</h4>
            <p><strong>Bet√§ubungsmittelgesetz</strong> - Controlled substance with medical use allowance.</p>
            <p><strong>Prescription status:</strong> Available through licensed physicians</p>
          </div>
          <div class="jurisdiction">
            <h4>üåç International Status</h4>
            <p><strong>Limited availability:</strong> Primarily available in German-speaking countries</p>
            <p><strong>Research compound:</strong> Limited research use in other jurisdictions</p>
            <p><strong>UN control:</strong> Not currently under international control conventions</p>
          </div>
        </div>
        
        <div class="prescription-regulations">
          <h4>üìã Prescription Regulations (Germany)</h4>
          <ul>
            <li><strong>Special prescription forms:</strong> Requires narcotic prescription pad (Bet√§ubungsmittelrezept)</li>
            <li><strong>Quantity limits:</strong> Maximum 30-day supply per prescription</li>
            <li><strong>Documentation:</strong> Pharmacies must maintain detailed records</li>
            <li><strong>Patient monitoring:</strong> Regular assessment for effectiveness and abuse</li>
            <li><strong>Specialist prescription:</strong> Often requires pain specialist or oncologist prescription</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Development</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1957</span>
          <p>First synthesized by German pharmaceutical company G√∂decke</p>
        </div>
        <div class="history-event">
          <span class="year">1960s</span>
          <p>Clinical development and early trials for analgesic use</p>
        </div>
        <div class="history-event">
          <span class="year">1970</span>
          <p>Introduced to German market as prescription analgesic</p>
        </div>
        <div class="history-event">
          <span class="year">1980s</span>
          <p>Growing recognition of abuse potential, diversion concerns</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Development of naloxone co-formulation as abuse deterrent</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Naloxone combinations become standard, reduced abuse rates</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Enhanced monitoring, prescription database implementation</p>
        </div>
      </div>

      <div class="development-context">
        <h4>üìà Development & Medical Context</h4>
        <div class="development-aspects">
          <div class="development-aspect">
            <h5>üá©üá™ German Pain Management</h5>
            <p>Tilidin was developed as part of Germany's approach to moderate pain management, filling the gap between weak opioids (codeine) and strong opioids (morphine). It became particularly popular for chronic pain conditions where tramadol was insufficient but morphine seemed excessive.</p>
          </div>
          
          <div class="development-aspect">
            <h5>üî¨ Pharmaceutical Innovation</h5>
            <p>The combination with naloxone represented an early example of abuse-deterrent formulation, predating similar strategies in other countries. This innovation helped maintain medical availability while reducing recreational abuse potential.</p>
          </div>
          
          <div class="development-aspect">
            <h5>üè• Clinical Adoption</h5>
            <p>Widely adopted in German pain clinics, orthopedic practices, and oncology units. Its dual mechanism (opioid + SNRI-like) made it particularly effective for neuropathic pain conditions common in chronic pain management.</p>
          </div>
        </div>
      </div>

      <div class="abuse-deterrent-history">
        <h4>üö´ Abuse Deterrent Development</h4>
        <div class="deterrent-evolution">
          <ul>
            <li><strong>Initial formulation:</strong> Pure tilidin with significant abuse potential</li>
            <li><strong>Abuse recognition:</strong> 1980s reports of injection and recreational use</li>
            <li><strong>Naloxone addition:</strong> Innovative 8:1 ratio development</li>
            <li><strong>Clinical success:</strong> Maintained therapeutic efficacy while reducing abuse</li>
            <li><strong>Regulatory approval:</strong> German authorities mandated combination formulations</li>
            <li><strong>International interest:</strong> Model for other abuse-deterrent opioid development</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research & Medical Applications</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>ü¶¥ Chronic Pain Management</h4>
          <p>Ongoing studies examine tilidin's effectiveness in various chronic pain conditions, particularly comparing its dual mechanism benefits to traditional opioids. Research focuses on neuropathic pain, osteoarthritis, and cancer pain management.</p>
        </div>
        
        <div class="research-item">
          <h4>üß† Neuropathic Pain</h4>
          <p>Investigation of tilidin's SNRI-like properties for diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia. The dual mechanism may provide superior analgesia for nerve-related pain conditions.</p>
        </div>
        
        <div class="research-item">
          <h4>üö´ Abuse Deterrent Technology</h4>
          <p>Research into improving naloxone co-formulations, developing tamper-resistant formulations, and studying real-world abuse deterrent effectiveness. Focus on maintaining therapeutic benefits while minimizing abuse potential.</p>
        </div>
        
        <div class="research-item">
          <h4>üß¨ Pharmacogenomics</h4>
          <p>Studies on CYP3A4 and CYP2C19 genetic variants affecting tilidin metabolism. Research aims to personalize dosing based on individual metabolic capacity and optimize therapeutic outcomes.</p>
        </div>
      </div>

      <div class="clinical-applications">
        <h4>üè• Current Medical Applications</h4>
        <div class="medical-uses">
          <div class="medical-use">
            <h5>Moderate to Severe Chronic Pain</h5>
            <p>Primary indication for various chronic pain conditions including osteoarthritis, rheumatoid arthritis, chronic back pain, and post-surgical chronic pain syndromes.</p>
          </div>
          
          <div class="medical-use">
            <h5>Cancer Pain Management</h5>
            <p>Used in oncology for cancer-related pain, particularly when morphine is not tolerated or contraindicated. Effective for both nociceptive and neuropathic cancer pain.</p>
          </div>
          
          <div class="medical-use">
            <h5>Neuropathic Pain Conditions</h5>
            <p>Increasingly used for diabetic neuropathy, post-herpetic neuralgia, and trigeminal neuralgia due to its dual mechanism providing both opioid and monoaminergic analgesia.</p>
          </div>
          
          <div class="medical-use">
            <h5>Palliative Care</h5>
            <p>Role in end-of-life pain management, particularly for patients who cannot tolerate stronger opioids or require multimodal analgesia approaches.</p>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section addiction-treatment">
      <h3>üîÑ Addiction & Dependence Management</h3>
      
      <div class="addiction-profile">
        <h4>Dependence Characteristics</h4>
        <div class="dependence-factors">
          <div class="dependence-factor">
            <h5>‚ö° Physical Dependence</h5>
            <ul>
              <li><strong>Timeline:</strong> Physical dependence develops within 1-2 weeks of regular therapeutic use</li>
              <li><strong>Tolerance:</strong> Analgesic tolerance develops gradually over weeks to months</li>
              <li><strong>Withdrawal syndrome:</strong> Typical opioid withdrawal with additional SNRI-like symptoms</li>
              <li><strong>Cross-dependence:</strong> Full cross-dependence with other mu-opioid agonists</li>
            </ul>
          </div>
          
          <div class="dependence-factor">
            <h5>üß† Psychological Dependence</h5>
            <ul>
              <li><strong>Abuse potential:</strong> Moderate compared to traditional opioids</li>
              <li><strong>Reinforcement:</strong> Less euphoric than morphine or oxycodone</li>
              <li><strong>Craving patterns:</strong> Both opioid craving and mood-related seeking</li>
              <li><strong>Naloxone deterrent:</strong> Significantly reduces injection abuse</li>
            </ul>
          </div>
        </div>
      </div>

      <div class="withdrawal-management">
        <h4>üîÑ Withdrawal Management</h4>
        <div class="withdrawal-approaches">
          <div class="withdrawal-approach">
            <h5>üíä Medical Tapering</h5>
            <ul>
              <li><strong>Gradual reduction:</strong> 10-25% dose reduction every 3-7 days</li>
              <li><strong>Extended-release transition:</strong> Switch to longer-acting formulations</li>
              <li><strong>Symptom management:</strong> Clonidine, gabapentinoids for withdrawal symptoms</li>
              <li><strong>Duration:</strong> 2-4 week taper for chronic users</li>
            </ul>
          </div>
          
          <div class="withdrawal-approach">
            <h5>üè• Inpatient Detoxification</h5>
            <ul>
              <li><strong>Medical monitoring:</strong> 24-hour supervision for severe dependence</li>
              <li><strong>Comfort medications:</strong> Comprehensive symptom management</li>
              <li><strong>Dual withdrawal:</strong> Address both opioid and SNRI-like withdrawal</li>
              <li><strong>Transition planning:</strong> Long-term pain management strategies</li>
            </ul>
          </div>
          
          <div class="withdrawal-approach">
            <h5>üîÑ Opioid Substitution</h5>
            <ul>
              <li><strong>Methadone transition:</strong> For severe dependence cases</li>
              <li><strong>Buprenorphine:</strong> Alternative for motivated patients</li>
              <li><strong>Dose conversion:</strong> Careful calculation needed</li>
              <li><strong>Stabilization:</strong> Address underlying pain conditions</li>
            </ul>
          </div>
        </div>
      </div>

      <div class="chronic-pain-considerations">
        <h4>üíä Chronic Pain Patient Considerations</h4>
        <ul>
          <li><strong>Legitimate need:</strong> Many tilidin-dependent patients have genuine pain conditions</li>
          <li><strong>Alternative analgesia:</strong> Non-opioid multimodal pain management</li>
          <li><strong>Psychological support:</strong> Address pain-related anxiety and depression</li>
          <li><strong>Functional restoration:</strong> Physical therapy, occupational therapy integration</li>
          <li><strong>Harm reduction:</strong> Supervised use if cessation not immediately possible</li>
          <li><strong>Interdisciplinary care:</strong> Pain specialists, addiction medicine, psychology</li>
        </ul>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.gelbe-liste.de/">Gelbe Liste</a> - German pharmaceutical database</li>
          <li><a href="https://www.apotheken-umschau.de/">Apotheken Umschau</a> - German pharmacy information</li>
          <li><a href="https://www.schmerzgesellschaft.de/">Deutsche Schmerzgesellschaft</a> - German Pain Society</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Addiction Support</h4>
        <ul>
          <li><a href="https://www.dhs.de/">DHS</a> - German Addiction Help Society</li>
          <li><a href="https://www.bzga.de/">BZgA</a> - Federal Centre for Health Education</li>
          <li><a href="https://www.suchthilfe.de/">Suchthilfe</a> - Addiction treatment directory</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Pain Management</h4>
        <ul>
          <li><a href="https://www.schmerzliga.de/">Deutsche Schmerzliga</a> - German Pain League</li>
          <li><a href="https://www.schmerzzentren.de/">Schmerzzentren</a> - Pain center directory</li>
          <li><a href="https://www.dgss.org/">DGSS</a> - German Pain Society</li>
        </ul>
      </div>
    </div>
  </div>

</div>